Brief: Amneal Announces Positive Interim Phase 4 Elevate-Pd Results With Crexont For Parkinson’S Disease
05/12/2025 13:01
Dec 5 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O: AMNEAL ANNOUNCES POSITIVE INTERIM PHASE 4 ELEVATE-PD RESULTS WITH CREXONT® FOR PARKINSON’S DISEASE AMNEAL PHARMA - 55 PATIENTS SHOW SUBSTANTIAL BENEFIT WITH CREXONT AMNEAL PHARMA: ELEVATE-PD STUDY IS ONGOING WITH LONGER-TERM DATA EXPECTED IN 2026 Source text: ID:nGNX4J5Bsp Further company coverage: AMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsUS FDA is working with manufacturers to boost estrogen patch supply amid access concerns (updated)
U.S. RESEARCH ROUNDUP- Intuit, MongoDB, Zscaler
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Mastercard, Starbucks, Meta